Telix Pharmaceuticals (TLX.AX) Stock Price
Telix Pharmaceuticals Price
Revenue has compounded at 228.4% per year over the past 7 years to 803.79 M USD. Telix Pharmaceuticals's net margin stands at -0.9%, up from -1,059.9% several years earlier. Analysts set a median price target of 16.16 USD, implying 46.5% above the current price. Of 17 analysts, 16 rate the stock a buy — an overall Buy consensus.
Telix Pharmaceuticals stock price
Telix Pharmaceuticals business model & stock analysis
Frequently asked questions about Telix Pharmaceuticals
The business model of Telix Pharmaceuticals Ltd revolves around the development and commercialization of molecularly targeted radiation (MTR) products. As a leading biopharmaceutical company, Telix focuses on producing innovative diagnostic and therapeutic solutions for patients suffering from cancer. By utilizing its expertise in radiopharmaceuticals and molecular targeting, Telix aims to enhance the precision and efficacy of cancer diagnosis, imaging, and treatment. Through collaborations with various partners, Telix strives to bring advanced diagnostic imaging technologies and personalized treatment options to healthcare professionals and patients worldwide. Telix Pharmaceuticals Ltd plays a crucial role in improving patient outcomes and advancing the field of nuclear medicine.
Telix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Telix Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the same sector, focusing on molecularly targeted radiation (MTR) therapies and diagnostic imaging products for oncology. These competitors include established players such as Advanced Accelerator Applications SA (a Novartis company), Bayer AG, Curium Pharmaceuticals, and Progenics Pharmaceuticals. Telix Pharmaceuticals Ltd distinguishes itself through its innovative radiopharmaceutical solutions, strategic collaborations, and ongoing clinical trials.
Telix Pharmaceuticals Ltd is an innovative biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for cancer diagnosis and treatment. Established in 2016, Telix has rapidly grown into a global player in the molecularly targeted radiation therapy field. The company has successfully acquired and developed a diverse portfolio of diagnostic and therapeutic products, leveraging its cutting-edge technology and strategic partnerships. Telix has made significant progress in clinical trials, regulatory approvals, and commercialization efforts, demonstrating its commitment to improving patient outcomes in oncology. With its dedicated team and robust pipeline, Telix Pharmaceuticals Ltd is poised to revolutionize cancer management through personalized and targeted radiopharmaceuticals.
Telix Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully completed its Phase III clinical trial for TLX591-CDx, a prostate cancer imaging agent. Additionally, Telix Pharmaceuticals received regulatory approval in the United States, Europe, and Canada for TLX591-CDx, allowing for its commercialization. Another notable achievement is the successful completion of a collaboration agreement with China Grand Pharma, expanding Telix's presence in the Chinese market. Furthermore, Telix Pharmaceuticals entered into a licensing agreement with ANMI SA, enhancing its product portfolio for molecular imaging. These achievements highlight Telix Pharmaceuticals' commitment to developing innovative solutions in the field of radiopharmaceuticals.
Telix Pharmaceuticals Ltd primarily operates in several countries and regions, including Australia, the United States, Europe, and Japan.
Telix Pharmaceuticals Ltd represents a strong commitment to improving the diagnosis and treatment of cancer. With a focus on molecularly targeted radiation therapy, the company aims to develop innovative radiopharmaceuticals that can deliver more precise and effective cancer treatments. Telix Pharmaceuticals embraces a patient-centered approach, continually striving to enhance patient outcomes and improve quality of life. The company is dedicated to fostering collaborations, driving scientific advancements, and delivering transformative therapies to individuals battling cancer. Telix Pharmaceuticals Ltd stands as a beacon of innovation, aiming to revolutionize the field of cancer medicine with its cutting-edge technologies and unwavering dedication to making a difference.
Analysts currently set an average price target of 16.97 USD for the Telix Pharmaceuticals stock (median: 16.16 USD), implying +53.8 % versus the latest price. The consensus is based on 17 analyst ratings.
17 analysts currently rate the Telix Pharmaceuticals stock: 16 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Telix Pharmaceuticals to generate revenue of 984.32 M USD and earnings per share of 0.08 USD.
Converted at the current exchange rate, the Telix Pharmaceuticals share trades at 9.84 EUR (11.03 USD).
The Telix Pharmaceuticals share (TLX.AX) is listed on 2 stock exchanges, including: ASX (TLX.AX).
Telix Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development and commercialization of diagnostic technologies and therapeutic products for oncology.
The expected revenue of Telix Pharmaceuticals is 984.32 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Telix Pharmaceuticals is 26.48 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Telix Pharmaceuticals is currently 140.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Telix Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Telix Pharmaceuticals is currently 3.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Telix Pharmaceuticals stock.
The Eulerpool Quality Score for Telix Pharmaceuticals is 3/10.
The ISIN of Telix Pharmaceuticals is AU000000TLX2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Telix Pharmaceuticals is A2H7JK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Telix Pharmaceuticals is TLX.AX. The ticker symbol is used to trade Telix Pharmaceuticals shares on the stock exchange.
Telix Pharmaceuticals stock
Telix Pharmaceuticals Peer Group
Telix Pharmaceuticals Ticker
Telix Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Telix Pharmaceuticals
Our stock analysis for Telix Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Telix Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.